Showing 71 - 80 of 132,476
Pharmaceutical firms spend billions of dollars to develop the next breakthrough drug and to maintain their market shares. We investigate how pharmaceutical firms use mergers and acquisitions to boost their innovation performance which has been found to result in better performance outcomes....
Persistent link: https://www.econbiz.de/10012502063
process R&D and on the product market. We examine how a merger affects the output, investment, and profits of firms, whether …We investigate the incentive and the welfare implications of a merger when heterogeneous oligopolists compete both in … firms have merger incentives, and, if so, whether such mergers are desirable from the viewpoint of social welfare. We also …
Persistent link: https://www.econbiz.de/10003921808
process R&D and on the product market. We examine how a merger affects the output, investment, and profits of firms, whether …We investigate the incentive and the welfare implications of a merger when heterogeneous oligopolists compete both in … firms have merger incentives, and, if so, whether such mergers are desirable from the viewpoint of social welfare. We also …
Persistent link: https://www.econbiz.de/10013156465
Government subsidies are often used to stimulate environment-friendly investment. We find that Chinese firms reduce … green investment as the uncertainty of subsidies rises. This effect is identified from weather-driven fluctuations in air … engage in less green R&D investment, patent applications, and research staff. Industries that are heavy emitters and those …
Persistent link: https://www.econbiz.de/10014350057
The paper clarifies how sunk costs can lead a rational incumbent to innovate less than an entrant. It also demonstrates that competition among incumbents yields less adoption of new and more efficient production technology than competition which includes entrants. The results suggest that policy...
Persistent link: https://www.econbiz.de/10012996869
Persistent link: https://www.econbiz.de/10011430453
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Patent-based measures are frequently used as indicators in empirical research on innovation and technology as well as on firms' strategies and organizational choices to characterize inventions or, more generally, innovative activities and the technological capabilities of organizations. A clear...
Persistent link: https://www.econbiz.de/10010258420
Patent-based measures are frequently used as indicators in empirical research on innovation and technological change. Currently, there is little evidence as to what extent patent-based indicators relate to product market outcomes. Using a unique dataset that links outcomes from product...
Persistent link: https://www.econbiz.de/10010497622
Patent settlements between originator and generic firms in the pharmaceutical industry have been challenged by antitrust and competition authorities in the U.S. and the EU. Particularly settlements with large "reverse payments" to generic firms raise the concern of collusive behaviour for...
Persistent link: https://www.econbiz.de/10011408141